Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–49.

Article  Google Scholar 

Zong L, Abe M, Seto Y, Ji J. The challenge of screening for early gastric cancer in China. Lancet. 2016;388(10060):2606.

Article  PubMed  Google Scholar 

Janjigian Y, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun H, Li K, Liu C, Yi C. Regulation and functions of non-mA mRNA modifications. Nat Rev Mol Cell Biol. 2023;24(10):714–31.

Article  CAS  PubMed  Google Scholar 

Li D, Shen L, Zhang X, Chen Z, Huang P, Huang C, Qin S. LncRNA ELF3-AS1 inhibits gastric cancer by forming a negative feedback loop with SNAI2 and regulates ELF3 mRNA stability via interacting with ILF2/ILF3 complex. J Exp Clin Cancer Res. 2022;41(1):332.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerken T, Girard C, Tung Y, Webby C, Saudek V, Hewitson K, Yeo G, McDonough M, Cunliffe S, McNeill L, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318(5855):1469–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Su R, Deng X, Chen Y, Chen J. FTO in cancer: functions, molecular mechanisms, and therapeutic implications. Trends Cancer. 2022;8(7):598–614.

Article  PubMed  Google Scholar 

Yang S, Wei J, Cui Y, Park G, Shah P, Deng Y, Aplin A, Lu Z, Hwang S, He C, et al. mA mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10(1):2782.

Article  PubMed  PubMed Central  Google Scholar 

Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Posta M, Győrffy B. Analysis of a large cohort of pancreatic cancer transcriptomic profiles to reveal the strongest prognostic factors. Clin Transl Sci. 2023;16(8):1479–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang H, Han Q, Zheng H, Wang J. MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. Cell Death Dis. 2022. https://doi.org/10.1038/s41419-021-04474-1.

Article  PubMed  PubMed Central  Google Scholar 

Juin A, Spence H, Machesky L. Dichotomous role of the serine/threonine kinase MAP4K4 in pancreatic ductal adenocarcinoma onset and metastasis through control of AKT and ERK pathways. J Pathol. 2024. https://doi.org/10.1002/path.6248.

Article  PubMed  Google Scholar 

Li L, Li Z, Meng X, Wang X, Song D, Liu Y, Xu T, Qin J, Sun N, Tian K, et al. Histone lactylation-derived LINC01127 promotes the self-renewal of glioblastoma stem cells via the cis-regulating the MAP4K4 to activate JNK pathway. Cancer Lett. 2023;579: 216467.

Article  CAS  PubMed  Google Scholar 

Chen K, Yuan X, Wang S, Zheng F, Fu Z, Shen Z, Cheng X, Wang Y, Tang S, Ni H, et al. MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage. Oncogene. 2023;42(18):1438–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding L, Jiang L, Xing Z, Dai H, Wei J. Map4k4 is up-regulated and modulates granulosa cell injury and oxidative stress in polycystic ovary syndrome via activating JNK/c-JUN pathway: an experimental study. Int Immunopharmacol. 2023;124: 110841.

Article  CAS  PubMed  Google Scholar 

Wan C, Chen W, Cui Y, He Z. MAP4K4/JNK signaling pathway stimulates proliferation and suppresses apoptosis of human spermatogonial stem cells and lower level of MAP4K4 is associated with male infertility. Cells. 2022. https://doi.org/10.3390/cells11233807.

Article  PubMed  PubMed Central  Google Scholar 

Siegel R, Giaquinto A, Jemal A. Cancer statistics. CA. 2024;74(1):12–49.

PubMed  Google Scholar 

Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064–74.

Article  PubMed  Google Scholar 

Kelly R, Ajani J, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203.

Article  CAS  PubMed  Google Scholar 

Li D, Xia L, Huang P, Wang Z, Guo Q, Huang C, Leng W, Qin S. Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in cancer metastasis: focusing on partial EMT and regulatory mechanisms. Cell Prolif. 2023;56(6): e13423.

Article  PubMed  PubMed Central  Google Scholar 

Liabeuf D, Oshima M, Stange D, Sigal M. Stem cells, Helicobacter pylori, and mutational landscape: utility of preclinical models to understand carcinogenesis and to direct management of gastric cancer. Gastroenterology. 2022;162(4):1067–87.

Article  CAS  PubMed  Google Scholar 

Grady W, Yu M, Markowitz S. Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer. Gastroenterology. 2021;160(3):690–709.

Article  CAS  PubMed  Google Scholar 

Li D, Xia L, Huang P, Wang Z, Guo Q, Huang C, Leng W, Qin S. Cancer-associated fibroblast-secreted IGFBP7 promotes gastric cancer by enhancing tumor associated macrophage infiltration via FGF2/FGFR1/PI3K/AKT axis. Cell Death Discov. 2023;9(1):17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin J, Zhan G, Liu J, Maimaitiyiming Y, Deng Z, Li B, Su K, Chen J, Sun S, Zheng W, et al. YTHDF2-mediated regulations bifurcate BHPF-induced programmed cell deaths. Nat Sci Rev. 2023. https://doi.org/10.1093/nsr/nwad227.

Article  Google Scholar 

Guirguis A, Ofir-Rosenfeld Y, Knezevic K, Blackaby W, Hardick D, Chan Y, Motazedian A, Gillespie A, Vassiliadis D, Lam E, et al. Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity. Cancer Discov. 2023;13(10):2228–47.

Article  PubMed  Google Scholar 

Wang L, Dou X, Chen S, Yu X, Huang X, Zhang L, Chen Y, Wang J, Yang K, Bugno J, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023;41(7):1294-1308.e1298.

Article  CAS  PubMed  Google Scholar 

Kan R, Chen J, Sallam T. Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation. Trends Genet. 2022;38(2):182–93.

Article  CAS  PubMed  Google Scholar 

Flamand M, Tegowski M, Meyer K. The proteins of mRNA modification: writers, readers, and erasers. Annu Rev Biochem. 2023;92:145–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shulman Z, Stern-Ginossar N. The RNA modification N-methyladenosine as a novel regulator of the immune system. Nat Immunol. 2020;21(5):501–12.

Article  CAS  PubMed  Google Scholar 

Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28(5):507–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Wu X, Li G, Lv G, Wang S. FTO promotes the stemness of gastric cancer cells. DNA Cell Biol. 2023;42(7):411–20.

Article  CAS  PubMed  Google Scholar 

González-Montero J, Rojas C, Burotto M. MAP4K4 and cancer: ready for the main stage? Front Oncol. 2023;13:1162835.

Article  PubMed  PubMed Central  Google Scholar 

Gao X, Gao C, Liu G, Hu J. MAP4K4: an emerging therapeutic target in cancer. Cell Biosci. 2016;6:56.

Article  PubMed  PubMed Central  Google Scholar 

Singh S, Roy R, Kumar S, Srivastava P, Jha S, Rana B, Rana A. Molecular insights of MAP4K4 signaling in inflammatory and malignant diseases. Cancers. 2023. https://doi.org/10.3390/cancers15082272.

Article  PubMed  PubMed Central  Google Scholar